DEF 14C: Propanc Biopharma Announces Reverse Stock Split to Enhance Financing Capabilities

Propanc Biopharma is set to execute a reverse stock split at a ratio between 1:10,000 and 1:100,000, approved by a majority stockholder, to improve its financing and capital raising ability.

Summary

• Propanc Biopharma, Inc. is notifying shareholders of a reverse stock split approved by the Board of Directors on August 7, 2024, and authorized via written consent by a majority stockholder.
• The reverse stock split will consolidate shares at a ratio between 1:10,000 and 1:100,000.
• The company believes this action is necessary to maintain and improve its financing and capital raising capabilities.
• As of August 7, 2024, there were 557,748,177 shares of Common Stock outstanding.
• The majority stockholder, holding approximately 50.01% of the voting equity, approved the reverse stock split.
• The reverse stock split will become effective 20 calendar days after the Information Statement is mailed to shareholders, pending FINRA approval.
• The primary purpose of the reverse stock split is to better position the company for future operations and financing.
• The reverse stock split will result in a reduction of outstanding shares to between approximately 5,575 and 55,748 shares, depending on the final ratio.
• Proportionate adjustments will be made to the exercise price and number of shares covered by outstanding options and warrants.
• The reverse stock split will create newly authorized shares of common stock, which could be used for various corporate purposes, including raising capital and acquisitions.
• The company does not currently have specific plans for issuing additional shares but convertible noteholders may elect to convert their notes into equity.
• The company's filings with the SEC, including annual and quarterly reports, are incorporated by reference and available for review.
• The company will provide a copy of the notice and information statement, without charge, to any shareholder upon written request.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While a reverse stock split can be a sign of financial difficulty, the company frames it as a strategic move to improve its financing capabilities. The high split ratio suggests significant challenges, but the company's focus on future growth tempers the negative implications.

Positives

• The reverse stock split is intended to improve the company's financing and capital raising ability.
• The action has been approved by a majority stockholder, ensuring its implementation.
• The reverse stock split will create newly authorized shares of common stock, providing flexibility for future corporate actions.
• The company is committed to providing shareholders with information and access to relevant documents.

Negatives

• The reverse stock split will significantly reduce the number of outstanding shares, which could be perceived negatively by some investors.
• The creation of newly authorized shares could potentially dilute existing shareholders' equity if these shares are issued in the future.
• The reverse stock split could make the company a less attractive target for acquisition due to the potential for dilution.

Risks

• The reverse stock split may not achieve the desired improvement in financing and capital raising ability.
• The creation of newly authorized shares could lead to dilution of existing shareholders' equity.
• The reverse stock split could be perceived negatively by the market, impacting the company's stock price.
• The company's convertible noteholders may elect to convert their convertible promissory notes into equity, which could further dilute existing shareholders.

Future Outlook

The company anticipates that the reverse stock split will better position it to continue and/or expand operations. The company has no other plans for the use of any additional shares of common stock and has no specific plans or proposals to issue additional shares, however, convertible noteholders may elect, at their sole option, to convert their convertible promissory notes into equity.

Management Comments

• The Board believes the Reverse Stock Split is necessary and advisable in order for the Company to maintain the Company's financing and capital raising ability.
• Accordingly, it is the Board's opinion that the Reverse Stock Split will better position the Company to continue and/or expand operations.

Industry Context

Reverse stock splits are often used by companies with low stock prices to increase their share price and potentially attract institutional investors or meet listing requirements. This action is not uncommon in the biopharmaceutical industry, where companies often need to raise capital for research and development.

Comparison to Industry Standards

• Many small-cap biotech companies have used reverse stock splits to maintain exchange listing compliance, such as Delcath Systems, Inc. which implemented a 1-for-10 reverse stock split.
• Other companies, like Titan Pharmaceuticals, Inc., have used reverse stock splits to improve their stock price and attract institutional investors.
• The specific ratio chosen by Propanc Biopharma (1:10,000 to 1:100,000) is relatively high compared to typical reverse stock splits, indicating a significant need to increase the share price.

Stakeholder Impact

• Shareholders will experience a reduction in the number of shares they hold, but their percentage ownership will remain the same (excluding fractional shares).
• The reverse stock split could impact the company's ability to attract new investors.
• Employees may be affected by the company's ability to secure financing and continue operations.

Next Steps

• File the Reverse Stock Split with FINRA.
• Await FINRA approval.
• Effect the Reverse Stock Split as soon as practicable following the twentieth (20th) calendar day following the date on which this Information Statement is mailed to the Stockholders.

Key Dates

Keywords

reverse stock split, Propanc Biopharma, financing, capital raising, shareholder, common stock, FINRA, dilution